Blog

The Exit Factor: Why M&amp;A is on the rise in HealthTech Wednesday, 17 June 2026Time: 9:00 AM - 9:40 AMTrack 1, Panel &nbsp; Forget IPOs. Europe’s healthtech story is increasingly being written by buyers. Corporates want fresh tech, investors want liquidity, and the cheques are getting bigger. By mid-2025 healthcare deal value had soared 87% to €31.8 billion, even as deal count slid 8% according to Nelson Advisors. In the UK, 168 healthtech exits landed by the end of 2024 against just 61 failures. M&amp;A is no longer a side strategy; it’s the headline act and primary way buyers access innovation, capability, and competitive edge.Source: <a href="https://hlth.com/events/europe/agenda/2026/the-exit-factor-why-m-and-a-is-on-the-rise-in-healthtech" data-mce-href="https://hlth.com/events/europe/agenda/2026/the-exit-factor-why-m-and-a-is-on-the-rise-in-healthtech">https://hlth.com/events/europe/agenda/2026/the-exit-factor-why-m-and-a-is-on-the-rise-in-healthtech</a>

Nelson Advisors HLTH Europe 2026 - The Exit Factor: Why M&A is on the rise in HealthTech

The healthcare technology landscape in early 2026 has transitioned from a period of venture-subsidised fragmentation into a disciplined era defined by industrial maturity and strategic consolidation. This "Great Rationalisation" is characterised by the emergence of scalable, profit-generating platforms that prioritize regulatory fortitude and deep clinical integration over simple documentation features.&nbsp; &nbsp;&nbsp; The market is witnessing a fundamental shift in product identity: the "AI scribe," once a standalone productivity tool, is being absorbed into comprehensive "AI care partner" ecosystems.This evolution is underpinned by a strategic push for sovereign scale and compliance moats, as evidenced by the landmark acquisitions of AutoMedica by Heidi Health and Juvoly by Tandem Health. These deals represent more than mere geographic expansion; they signify a pursuit of "Regulatory Darwinism," where the ability to navigate complex medical device regulations like the EU's MDR and the UK's MHRA frameworks determines long-term viability.The medical AI sector’s consolidation in early 2026 has successfully bridged the gap between documentation and clinical reasoning. Heidi Health’s acquisition of AutoMedica and Tandem Health’s acquisition of Juvoly highlight the two necessary pillars of global expansion: regulatory depth and localized market scale. As the industry moves into a period of industrialisation, the focus must remain on building "Clinical-Grade Integrity" that is free from commercial bias and grounded in rigorous evidence.&nbsp; &nbsp;&nbsp; The upcoming UK National Commission framework will be the final piece of the puzzle, providing the governance "rulebook" required to turn these promising tools into essential national infrastructure. For the global healthcare system, the "Industrialisation of Care" offers a tangible path toward reducing burnout, improving capacity, and finally allowing clinicians to focus on what matters most: the patient.Read our report in full here <a href="https://www.healthcare.digital/single-post/healthcare-ai-s-evolution-from-the-scribe-wars-toward-the-clinician-ai-stack">https://www.healthcare.digital/single-post/healthcare-ai-s-evolution-from-the-scribe-wars-toward-the-clinician-ai-stack</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a> &nbsp;

Healthcare AI's Strategic Pivot: From Documentation to Clinical Reasoning

Nelson Advisors has been invited to mentor and judge the MedTech Innovator 2026 programme alongside a panel of esteemed US and European industry executives. &nbsp;&nbsp; Now in its 13th year, MedTech Innovator, the world’s largest medtech accelerator continues to identify the most promising medical device, diagnostic, and digital health startups developing innovative tools to improve patient care. Source: <a href="https://medtechinnovator.org">https://medtechinnovator.org</a>MedTech Innovator is the world's largest accelerator for medical device, digital health, and diagnostic companies. Our mission is to improve patients' lives by accelerating the growth of companies transforming healthcare worldwide. &nbsp;&nbsp; "According to Silicon Valley Bank’s CipherBio, MedTech Innovator is the largest accelerator of Life Science companies in the world. The dominant part of our portfolio is Medical Devices, in addition to our leadership position as an accelerator of diagnostics, digital health, and life science tools technologies. 93% of our portfolio are still in business or have been acquired, and 86% of our companies have raised equity financing. In Q1 2023, approximately 30% of all funds raised in the medtech sector went to a graduate of MedTech Innovator." &nbsp;&nbsp; Our corporate partners include leading manufacturers like Johnson &amp; Johnson, Dexcom, NIPRO Medical Corp., Olympus Medical Systems Group, W. L. Gore &amp; Associates, Asahi Intecc, Edwards Lifesciences, Fujikura, Jabil Healthcare, Maxim Integrated Ventures. and many others. They participate as thought leaders, application reviewers, event judges, and accelerator mentors. &nbsp;&nbsp; Hundreds of investors like RCT Ventures, Aphelion Capital, Life Science Angels, Healthtech Capital, Sofinnova Partners, Vensana, Treo, Hunniwell Lake Partners, Seroba Life Sciences participate as application reviewers, mentors, and judges. &nbsp;&nbsp; <a href="https://medtechinnovator.org/about-us/">https://medtechinnovator.org/about-us/</a>MedTech Innovator is the world’s largest accelerator of medical technology companies, with a mission to improve the lives of patients by accelerating the growth of transformative health care startups.&nbsp;Along with its sibling programs, BioTools Innovator and MedTech Innovator Asia Pacific, the organization provides founders with mentorship, exposure to industry leaders, and access to funding opportunities.&nbsp; Each year, thousands of startups compete for a place in the programs’ cohorts, gaining global visibility and connections that help bring their innovations to market faster.

Nelson Advisors invited to judge the MedTech Innovator 2026 Programme

Nelson Advisors Partner Lloyd Price asked to Judge the 'HealthInvestor Power List Awards' recognising the most effective, inspiring and influential leaders in Health and Social Care.The HealthInvestor Power List celebrates effective, inspiring and influential figures in health and social care, including standout leaders, investors and advisors to the sector.Entries for the HealthInvestor Power List 2026 will open in May 2026.Nexus Media Group &nbsp;&nbsp; The Awards are hosted by Nexus Media Group, a leading B2B publishing and events company for the health, social care, seniors housing, education, early years and property sectors. &nbsp;&nbsp; Nexus Media Group is a publishing and events company, which focuses on the health, education, early-years and property sectors. Our range of established media titles and sector-leading events provide market intelligence and business connections, underpinned by a long-standing commitment to editorial excellence. &nbsp; Established in 2004, our London-based team of journalists and sector experts provide insight and introductions to complex marketplaces.Source: <a href="https://healthinvestorpowerlist.com/judges-2025/" data-mce-href="https://healthinvestorpowerlist.com/judges-2025/">https://healthinvestorpowerlist.com/judges-2025/</a>

Nelson Advisors joins expert judging panel for HealthInvestor Power List Awards

Since 2013, EquityZen has made it easy to buy and sell shares in the private companies &nbsp;aspiring to transform our world.EquityZen is a pioneer in democratizing private markets investing, offering convenient access to investment opportunities via our funds, and a proven track record of successful private placements across a wide range of companies.Abridge is a medical conversation AI startup that structures and summarizes medical conversations for doctors and patients.Abridge develops generative AI technology designed to automate clinical documentation by recording and summarizing medical conversations directly into Electronic Medical Records (EMRs). The company aims to reduce administrative burdens for healthcare providers, thereby allowing clinicians to focus primarily on patient care.Macroeconomic Headwinds and Market Consolidation: The healthcare AI sector is entering a projected "collapse of point solutions" in 2026. Health systems, facing tighter margins due to the One Big Beautiful Bill Act (OBBBA) and expiring ACA subsidies, are increasingly consolidating their tech stacks. This creates a "maturity wall" where Abridge must prove hard ROI rather than just "soft" metrics like time saved. Competitively, the risk of "platform capture" by EHR giants like Epic, who may eventually develop native, low-cost alternatives, remains a primary long-term threat to Abridge’s premium pricing model.Source: <a href="https://equityzen.com/company/abridged1a4/" data-mce-href="https://equityzen.com/company/abridged1a4/" data-mce-selected="inline-boundary">https://equityzen.com/company/abridged1a4/﻿</a>Reference:<a href="https://www.healthcare.digital/single-post/why-do-founders-and-investors-fear-an-ai-bubble-could-burst-in-healthcare-in-2026" data-mce-href="https://www.healthcare.digital/single-post/why-do-founders-and-investors-fear-an-ai-bubble-could-burst-in-healthcare-in-2026">https://www.healthcare.digital/single-post/why-do-founders-and-investors-fear-an-ai-bubble-could-burst-in-healthcare-in-2026</a>

Nelson Advisors referenced in EquityZen’s Abridge (ABRI) company and share analysis

Nelson Advisors referenced in Saudi British Joint Business Council and Arab British Chamber of Commerce Report.The year 2025 is a landmark for UK healthtech, with nearly half of all healthcare investment now channelled into AI-powered companies and digital solutions. In the first quarter, healthtech startups raised £1.35 billion, propelled by world-leading deals such as Isomorphic Labs’ £470 million funding round for AI-driven drug discovery4. The “Golden Triangle” of London, Oxford and Cambridge remains the crucible for healthtech research and innovation, but regional clusters, such as Manchester’s Science Park, demonstrate how infrastructure and local partnerships are furthering nationwide progress (5).The sector’s focus areas include AI-driven diagnostics, predictive analytics through digital twins and multiomic data, health data infrastructure, and increasingly, solutions aimed at personalised care and home-based health monitoring. Government investments, including a £600 million boost for health data research, are accelerating this transformation and securing the UK’s place at the frontier of global digital health innovation (6).5) <a href="https://nelsonadvisors.co.uk/blog/future-trends-for-uk-healthtech-investment">https://nelsonadvisors.co.uk/blog/future-trends-for-uk-healthtech-investment</a>6) <a href="https://nelsonadvisors.co.uk/blog/future-trends-for-uk-healthtech-investment">https://nelsonadvisors.co.uk/blog/future-trends-for-uk-healthtech-investment</a>Source: <a href="https://www.allurentis.com/_files/ugd/ff7369_e1366965c76745f8b5affe33d91be44a.pdf?index=true" data-mce-href="https://www.allurentis.com/_files/ugd/ff7369_e1366965c76745f8b5affe33d91be44a.pdf?index=true">https://www.allurentis.com/_files/ugd/ff7369_e1366965c76745f8b5affe33d91be44a.pdf?index=true</a>

Nelson Advisors

Blog

Nelson Advisors HLTH Europe 2026 - The Exit Factor: Why M...

Healthcare AI's Strategic Pivot: From Documentation to Cl...

Nelson Advisors invited to judge the MedTech Innovator 20...

Nelson Advisors joins expert judging panel for HealthInve...

Nelson Advisors referenced in EquityZen’s Abridge (ABRI) ...

Nelson Advisors referenced in Saudi British Joint Busines...